218 related articles for article (PubMed ID: 17581351)
21. Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.
Jordheim LP; Ribrag V; Ghesquieres H; Pallardy S; Delarue R; Tilly H; Haioun C; Jardin F; Demangel D; Salles GA; Dumontet C
Haematologica; 2015 May; 100(5):e204-6. PubMed ID: 25637052
[No Abstract] [Full Text] [Related]
22. Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
Chan H; Jackson S; McLay J; Knox A; Lee J; Wang S; Issa S
Leuk Lymphoma; 2016 Nov; 57(11):2584-92. PubMed ID: 26943235
[TBL] [Abstract][Full Text] [Related]
23. Sarcoid-like Histiocytic Proliferations in Patients With Lymphoma Can Be FDG-avid Concerning for Refractory or Recurrent Disease.
Cayci Z; Ozturk K; Ustun C; Omer AK; Dincer E; Sachs Z; Peterson BA; Linden MA
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e597-e601. PubMed ID: 31548163
[No Abstract] [Full Text] [Related]
24. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma.
Nieuwenhuizen L; Verzijlbergen FJ; Wiltink E; Grutters JC; Biesma DH
Haematologica; 2008 Aug; 93(8):1267-9. PubMed ID: 18556403
[No Abstract] [Full Text] [Related]
25. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
[TBL] [Abstract][Full Text] [Related]
26. [Skin lesions in a female patient with non-Hodgkin lymphoma].
Ducasse VO; Pintado JA; Gordon MM; Oyonarte MC
Enferm Infecc Microbiol Clin; 2007; 25(7):489-90. PubMed ID: 17692217
[No Abstract] [Full Text] [Related]
27. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
28. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Limat S; Daguindau E; Cahn JY; Nerich V; Brion A; Perrin S; Woronoff-Lemsi MC; Deconinck E
J Clin Pharm Ther; 2014 Apr; 39(2):168-74. PubMed ID: 24384030
[TBL] [Abstract][Full Text] [Related]
29. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M; Yamamoto G; Imai Y; Kurokawa M
Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
[No Abstract] [Full Text] [Related]
30. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
31. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
32. Necrotizing leukoencephalopathy following CHOP chemotherapy.
Blaes AH; Santa-Cruz KS; Lee CK; Hui SK; Peterson BA
Leuk Res; 2008 Oct; 32(10):1611-4. PubMed ID: 18378307
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
[TBL] [Abstract][Full Text] [Related]
34. Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.
Terenghi F; Ardolino G; Nobile-Orazio E
J Peripher Nerv Syst; 2007 Jun; 12(2):142-3. PubMed ID: 17565540
[No Abstract] [Full Text] [Related]
35. Effect of R-CHOP chemotherapy on liver and mediastinal blood pool (18)F-FDG standardized uptake values in patients with non-Hodgkin's lymphoma.
Kaya B; Dostbil Z; Ismailoglu M; Tasdemir B; Sahin O
Clin Imaging; 2015; 39(4):632-5. PubMed ID: 25709112
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
37. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
Korolenko VO; Gershanovich ML; Tikhonova VV
Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
[No Abstract] [Full Text] [Related]
38. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.
Kornacker M; Kraemer A; Leo E; Ho AD
Ann Hematol; 2002 Feb; 81(2):103-5. PubMed ID: 11907791
[TBL] [Abstract][Full Text] [Related]
39. [Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].
Kato H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():636-41. PubMed ID: 25831838
[No Abstract] [Full Text] [Related]
40. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
Shimazu Y; Nohgawa M
J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
